GV.PA Genomic Vision SA EURONEXT 23 Mar 2026: Intraday most-active, volume spike

GV.PA stock opened the EURONEXT session at €0.002 (exact €0.0018) on 23 Mar 2026 and posted a 5.88% intraday rise as volume surged to 38,489,238.00 shares. The move makes Genomic Vision SA (GV.PA) one of the most active small-caps in Europe today. Traders are reacting to thin-cap liquidity, stretched technical averages and company partnerships in diagnostics. We examine trading patterns, valuation metrics and the short-term outlook for investors and active traders on EURONEXT.

Intraday snapshot of GV.PA stock

Genomic Vision SA (GV.PA) trades on EURONEXT in Europe and is at €0.002 (last trade exact €0.0018), up 5.88% from the previous close of €0.0017. The intraday range is €0.0015 to €0.0020 and volume is 38,489,238.00, relative volume 2.71 versus average 14,217,513.00. Market cap stands at €693,191.00, underscoring a microcap profile with outsized percentage moves on modest order flow.

News, partnerships and what could be moving the price

Genomic Vision lists alliances with Quest Diagnostics and research agreements with Institut Pasteur and La Timone Hospital; such collaborations can support commercial uptake of the FiberVision platform. No fresh company press release appears today, so the intraday activity likely reflects liquidity and sector rotations rather than new fundamentals. For broader market context on financial news flows, see coverage from Seeking Alpha and reporting in the Wall Street Journal.

Fundamentals and valuation of Genomic Vision (GV.PA)

GV.PA shows trailing EPS: -0.11 and a negative PE: -0.02, reflecting losses. Price-to-sales is 0.47 while enterprise value to sales is 1.60, indicating the market values the company’s revenue modestly despite losses. Cash per share is €0.006 and shareholders’ equity per share is negative at -0.01, signalling balance-sheet strain and continued need for financing in the near term.

Technicals, liquidity and volatility for GV.PA

Short-term technicals show heavy discount to moving averages: 50-day avg €0.005 and 200-day avg €0.014, consistent with a long downtrend from the year high €0.094. The stock’s relative volume 2.71 and average daily volume 14,217,513.00 suggest intraday squeezes are common. With bid-ask spreads wide on microcaps, traders should expect order slippage and fast percentage moves.

Meyka grade and model overview

Meyka AI rates GV.PA with a score out of 100: 62.45 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score blends weak fundamentals and thin liquidity with potential upside from product partnerships; grades are informational and not financial advice.

Risks, catalysts and trading considerations for GV.PA

Key risks include negative operating margins, current ratio 0.91, and long cash conversion cycles. Catalysts would be confirmed commercial roll-outs of FiberVision, new contracts with diagnostic labs, or a capital raise that stabilises cash runway. For short-term traders, high volume days and spikes in order flow drive price discovery; for investors, the path to profitability and successful deployments matters most.

Final Thoughts

Price action on 23 Mar 2026 shows GV.PA stock as a highly active microcap on EURONEXT with €0.002 last trade (exact €0.0018) and 38,489,238.00 shares exchanged. Fundamentals show negative earnings (EPS -0.11) and strained equity, while partnerships in diagnostics support long-term optionality. Meyka AI’s forecast model projects a 12-month reference price of €0.0040, implying an upside of 122.22% versus the exact last trade €0.0018. Forecasts are model-based projections and not guarantees. Given the B / HOLD grade, we highlight that active traders may target short-term momentum, while longer-term investors should wait for clearer revenue traction or a balance-sheet improvement. For live orderbook detail and alerts visit the Meyka platform for real-time AI-powered market analysis and the GV.PA stock page: GV.PA on Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.